Cellectis bands together with US-partner to develop meganucleases
Paris, France - Cellectis is joining forces with US-based Pregenen to build up a common nuclease platform and develop new vectorisation technologies. The French genome engineering specialist announced the signing of a collaboration agreement with the American biotechnology start-up company. The decision comes only days after André Choulika, Founder of Cellectis and CEO since the company's inception, has taken over the post of Chairman of the Board as well. Cellectis is on its way to become one of the world's more innovative genome engineers. A few months ago the company's researchers presented the first synthetic TAL-effector, which is based on vectors used by the bacterium Xanthomonas and allows the cutting of DNA at a preselected point. The collaboration agreement focuses primarily on meganucleases and advanced
meganuclease vector technologies. The agreement also includes the development of meganucleases for use in key therapeutic applications. "Our combined expertise will produce the most advanced genome engineering
reagents available", said Choulika in a statement. Pregenen is a spinoff from the Northwest Genome Engineering Consortium, a group that brings in renowned international researchers from the Seattle Children's Research Institute, the Fred Hutchinson Cancer Research Center (Seattle) and the University of Washington.